Literatuurlijst op de website

[1] Kirchhof P et al., Europace. 2016 Nov;18(11):1609-1678.

[2] AF Association, . Arrhythmia Alliance Group,

[3] Lloyd-Jones DM et al. Circulation 2004; 110(9):1042-1046.

[4] Feinberg WM et al., Arch Intern Med. 1995 Mar 13;155(5):469-73

[5] Jhawar MB et al., J Blood Med. 2012;3:1-13

[6] Connolly SJ et al. NEJM 2009.

[7] Healey JS et al. Circulation 2012 Jul 17; 126(3):343-348.

[8] Granger CB et al. NEJM 2011 Sep 15; 365(11):981-992

[9] Dilaveris PE et al., Clin Cardiol. 2017 Jun;40(6):413-418

[10] Kannel WB and Benjamin EJ. Status of the epidemiology of atrial fibrillation. Med Clin North Am. 2008;92(1):17–40.

[11] Camm AJ, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31(19):2369-429.

[12] Fuster V, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation. Circulation. 2006;114(7):e257-354.

[13] 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal. 2016;37:2893–2962. doi: 10.1093/eurheartj/ehw210

[14] Friberg J, et al. Rising rates of hospital admissions for atrial fibrillation. Epidemiology. 2003;14(6):666-72.

[15] Arbelo E, et al. Contemporary management of patients undergoing atrial fibrillation ablation: in-hospital and 1-year follow-up findings from the ESC-EHRA atrial fibrillation ablation long-term registry. European Heart Journal. 2017. doi: 10.1093/eurheartj/ehw564

[16] Go AS, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285(18):2370-5.

[17] Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, Gillum RF, Kim YH, McAnulty JH Jr, Zheng ZJ, Forouzanfar MH, Naghavi M, Mensah GA, Ezzati M, Murray CJ. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation 2014;129:837–847.

[18] Colilla S, Crow A, Petkun W, Singer DE, Simon T, Liu X. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol 2013;112:1142–1147.

[19] Gustavsson A, Svensson M, Jacobi F et al. Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 2011;21:718–79

[20] Calkins H et al., Europace. 2018 Jan 1;20(1):e1-e160. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgicalablation of atrial fibrillation


[22] European Stroke Organisation (ESO) Executive Committee. Cerebrovasc Dis. 2008;25(5):457-507. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008.

[23] Carlos M et al., Exploring patients’ knowledge and perceptions of oral anticoagulation therapies and antidotes. Abstract. ESPACOMP 2017 Budapest. .


[25] Ref. Connoly SJ et al. NEJM 2009.,

[26] Healey JS et al. Circulation 2012 Jul 17: 126(3):342-348.

[27] Ferguson C. et al., Eur J Cardiovasc Nurs. 2017 Mar;16(3):178-180. Partnering with patients in shared decision-making for stroke prevention in atrial fibrillation

[28] Palacio AM, et al. Patient Prefer Adherence 2015;9:133–138.